Press Releases

View current press releases

2021

U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration
August 3, 2021

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
July 24, 2021

Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at the 2021 ASCRS ASOA Annual Meeting
July 19, 2021

William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors
June 22, 2021

Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting
April 27, 2021

2020

Bausch Health to Acquire Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics
September 21, 2020

2019

Allegro Ophthalmics to Present Clinical Research on the Company’s Novel Integrin-Regulating Portfolio at the American Academy of Ophthalmology Annual Meeting
October 8, 2019

Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting
September 3, 2019

Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019
July 24, 2019

Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration
June 4, 2019

Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease
May 14, 2019

Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting
April 30, 2019

Allegro Ophthalmics Expands Its Anti-Integrin Portfolio with New Front-of-the-Eye Drug Candidate ALG-1007 for the Treatment of Dry Eye Disease
April 25, 2019

Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to the Company’s Board of Directors
April 9, 2019

2018

Allegro Ophthalmics Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEO
August 21, 2018

2017

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate® In Patients With Diabetic Macular Edema
August 09, 2017

Allegro Ophthalmics Secures $10.7 Million In Private Financing
July 24, 2017

Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs
March 07, 2017

2016

Allegro Ophthalmics Completes Enrollment In DEL MAR Phase 2b, Stage 2 Clinical Trial Of Luminate® For The Treatment Of Diabetic Macular Edema
December 15, 2016

December 15, 2016 William J. Link, PhD, Joins Allegro Ophthalmics’ Board Of Directors
November 21, 2016

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2b Trial Evaluating Luminate® In Patients With Diabetic Macular Edema
October 13, 2016

Allegro Ophthalmics Announces Last Patient Enrolled In PACIFIC Phase 2b Clinical Trial Of Luminate® For Non-Proliferative Diabetic Retinopathy
October 03, 2016

Ron Kurtz, MD, And Mark Livingston Join Allegro Ophthalmics’ Board Of Directors
August 01, 2016

Allegro Ophthalmics Announces Two Executive Promotions
March 15, 2016

Allegro Ophthalmics Announces Last Patient Enrolled In Del Mar Phase 2b Clinical Trial Of Luminate ® For The Treatment Of Diabetic Macular Edema
January 05, 2016